| 24.55 Real-Time Quote |  +1.43 / +6.19%Today’s Change | 11.02 Today|||52-Week Range 50.51 | -29.86% Year-to-Date |
| Infinity Pharmaceuticals (INFI) Shares Cross Below 200 DMA May 16 / TheStreet.com | Narrower than Expected Loss at Infinity - Analyst Blog May 09 / Zacks.com |
| Previous close | 23.12 |
| Today’s open | 22.85 |
| Day’s range | 22.42 - 24.70 |
| Volume | 758,196 |
| Average volume (3 months) | 1,080,775 |
| Market cap | $1.1B |
| Dividend yield | -- |
| Earnings growth (last year) | -13.33% |
| Earnings growth (this year) | -44.38% |
| Earnings growth (next 5 years) | +28.00% |
| Revenue growth (last year) | -49.22% |
| P/E ratio | NM |
| Price/Sales | 23.56 |
| Price/Book | 3.54 |
| Today’s change | Today’s % change | |
|---|---|---|
| TSROTESARO Inc | -0.06 | -0.17% |
| PDLIPDL BioPharma Inc | +0.04 | +0.48% |
| SRPTSarepta Therapeutics... | +0.88 | +2.42% |
| ACADACADIA Pharmaceutica... | -0.03 | -0.22% |
| Next reporting date | August 7, 2013 |
| EPS forecast (this quarter) | -$0.61 |
| Annual revenue (last year) | $47.1M |
| Annual profit (last year) | -$54.0M |
| Net profit margin | -114.54% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Adelene Q. Perkins, MBA |
CFO, Secretary, Treasurer & CAO Lawrence E. Bloch, MD, MBA |
Corporate headquarters Cambridge, Massachusetts |
.
